| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Sales | 1,120,121 | - | 1,264,638 | |
| Cost of sales | 716,962 | - | 771,225 | |
| Gross profit | 403,159 | 0 | 493,413 | |
| Research and development | 581,612 | - | 771,180 | |
| Unrealized gain (loss), foreign currency transaction, before tax | - | - | 19,310 | |
| General and administrative | 1,532,015 | - | 1,421,926 | |
| Amortization and depreciation | 53,202 | - | 54,579 | |
| Foreign exchange (gain) loss | -56,994 | - | - | |
| Total operating expenses | 2,223,823 | 0 | 2,228,375 | |
| Interest and other income | 93,765 | - | 57,094 | |
| Loss before income tax expense | -1,726,899 | 0 | -1,677,868 | |
| Net loss for the period | -1,726,899 | - | -1,677,868 | |
| Basic (in dollars per share) | -0.44 | -1.94 | -2.71 | |
| Basic (in shares) | 3,954,549 | 1,095,973 | 620,127 | |
| Diluted (in dollars per share) | -0.44 | -1.94 | -2.71 | |
| Diluted (in shares) | 3,954,549 | 1,095,973 | 620,127 | |
InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. (INM)